Top Companies in Liquid Biopsy

The liquid biopsy market is projected to reach USD 7.05 billion by 2030 from USD 4.03 billion in 2025, at a CAGR of 11.8% during the forecast period. The liquid biopsy market is growing due to the increasing number of cancer cases and the rising need for, accurate and non-invasive testing methods. It uses a simple blood sample, making it safer and more convenient than traditional tissue biopsies. Technological advancements such as NGS and digital PCR have improved test sensitivity and reliability. Liquid biopsy applications are also expanding into prenatal screening and organ transplant monitoring. Supportive government frameworks and increasing funding investments are also expected to drive market growth.

• In February 2025, Myriad Genetics, Inc. (US) entered into an agreement with INTERLINK Care Management, Inc. (US) to improve education & access to hereditary cancer testing.
• In June 2024, Natera, Inc. (US) launched Prospera Heart with Donor Quantity Score (DQS), expanding the Prospera platform’s capabilities in detecting rejection in heart transplant patients.

The key players in this market are Natera, Inc. (US), Guardant Health (US), Myriad Genetics, Inc. (US), Illumina, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN (Netherlands), Thermo Fisher Scientific Inc. (US), Bio-Rad Laboratories, Inc. (US), Exact Sciences Corporation (US), Sysmex Corporation (Japan), and maxhealth (US), among others.

To know about the assumptions considered for the study download the pdf brochure

Natera, Inc. (US) focuses heavily on R&D capabilities to enhance its portfolio of cell-free DNA-based tests to improve clinical decision-making across oncology, transplant, and reproductive health. Its investments in R&D and capital allocation strategies help fuel its future growth and ability to remain competitive. The company’s strategies, including collaborations and acquisitions, aim to solidify its liquid biopsy market position further.

Guardant Health (US) holds a significant share in the liquid biopsy market, supported by its broad distribution network spanning the Americas, Europe, the Middle East & Africa, and Asia Pacific. The company maintains a strong market presence by offering innovative, high-quality products across the entire value chain. Guardant Health emphasizes research and development and pursues organic growth strategies to reinforce its market position. For instance, in June 2025, the company’s Shield multi-cancer detection (MCD) test received Breakthrough Device designation from the US FDA. This blood-based test utilizes methylation analysis to detect various cancers, including bladder, colorectal, lung, and pancreatic, in individuals aged 45 and older at average risk.

Market Ranking

The top five layers in the liquid biopsy market are Natera, Inc. (US), Guardant Health (US), Myriad Genetics, Inc. (US), Illumina, Inc. (US), and F. Hoffmann-La Roche Ltd. (Switzerland).

Natera, Inc. (US) plays a key role in the liquid biopsy market with its service-based model, offering clinically validated oncology and organ transplant care tests. Guardant Health (US) operates a vertically integrated model, combining test development, bioinformatics, and commercial partnerships to advance blood-based cancer diagnostics across multiple stages of care. Myriad Genetics, Inc. (US) offers precision medicine solutions, including liquid biopsy-based assays focused on hereditary cancer risk assessment and tumor profiling. Illumina, Inc. (US) supports the market as a core technology provider, offering next-generation sequencing systems and data tools that power many liquid biopsy applications. F. Hoffmann-La Roche Ltd. (Switzerland) leverages its global presence and regulatory expertise to drive the adoption of liquid biopsy in oncology through integrated diagnostic offerings. These companies shape a dynamic market driven by clinical innovation, expanding applications, and the growing demand for non-invasive testing.

Related Reports:

Liquid Biopsy Market by Product & Service (Kits, Instruments), Circulating Biomarker (ctDNA, cfDNA, CTC), Technology (NGS, PCR), Application (Lung, Breast, Prostate Cancer), Sample Type (Blood, Urine, CSF), End User (Hospitals) - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com